From: Factors Confounding the Athlete Biological Passport: A Systematic Narrative Review
Authors | Subjects | Interventions | [Hb] | Ret% | OFFs | Hct | PV |
---|---|---|---|---|---|---|---|
rhEPO doping | Â | Â | Â | Â | Â | Â | Â |
Bejder, Aachmann-Andersen et al. [15] | Recreational athletes (n = 16) | Sixteen subjects received either 65 IU rhEPO·kg−1 every second day for 2 weeks (G1/normal-dose) or 390 IU rhEPO·kg−1 on 3 consecutive days (G2/high-dose) for 13 d in a randomised, placebo-controlled, double-blind crossover design | =/= | ↑ + 81% | ↓ − 14% | – | – |
(NS) | ↑ + 135% (11 d) | ↓ − 21% (11 d) | |||||
 | ↓ − 26% | ↑ + 18% | |||||
 | ↓ − 21% | ↑ + 13% | |||||
 | (25 d) | (25 d) | |||||
Bornø et al. [16] | Recreational athletes (n = 24) | Twenty-four human subjects divided into three groups with eight subjects each were injected with rhEPO. The G1 and G2 groups received rhEPO for a 4-week period with 2 weeks of boosting followed by 2 weeks of maintenance and a washout period of 3 weeks. G3 received rhEPO for a 10-week period: boost (3 weeks/T1), maintenance (7 weeks/T2) and washout (1 week/T3) | = | ↑ | ↓ | – | – |
(T1) | (T1) | (T1) | |||||
↑ | ↓ | ↑ | |||||
(T3) | (T3) | (T3) | |||||
Clark et al. [17] | Recreational athletes (n = 16) | Eight subjects were assigned to receive six subcutaneous high-doses of 250 IU·kg−1 of rhEPO over 2 weeks (G1) while eight other subjects were assigned to receive six high-doses plus nine rhEPO micro-doses over a further 3 weeks (G2) | ↑ + 1.5 |  + 0.7% | ↓ − 37pt | ↑ + 6% | ↓ − 6dL |
↑ + 2.8 g·dL−1 |  + 1.0% | ↓ − 17pt | ↑ + 10% | ↓ − 2dL | |||
(2 weeks) | (2 weeks) | ↑ (2 weeks) | (2 weeks) | (2 weeks) | |||
 |  | ↑ (4 weeks) |  |  | |||
Ashenden et al. [18] | Recreational athletes (n = 10) | Ten subjects were given twice-weekly intravenous micro-dose injections of rhEPO for up to 12 weeks. All subjects received the same total quantity of rhEPO (adjusted for body weight) during the titration phase | = | = | = | – | – |
 |  | (NS) | (NS) | (NS) |  |  | |
Haile et al. [19] | Runners (n = 20) | Twenty well-trained Kenyan endurance runners living and training at approximately 2150 m received rhEPO injections of 50 IU·kg−1 body mass every 2 d for 4 weeks. This cohort (KEN) was compared with a previously published cohort (SCO) of 19 Scottish endurance-trained men based at or near sea level | ↑ + 10% | ↑ | ↓ | ↑ + 10% | – |
(4Â weeks) | (4Â weeks) | (4Â weeks) | (4Â weeks) | ||||
 |  | ↑ |  | ||||
 |  | (6 weeks) |  |